Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21738149 | 0.87 | HRH3 (0.39) | HRH3HTTLMNACHRNB2CHRNA3 | |
| SCHEMBL26139061 | 0.84 | HRH3 (0.45) | HRH3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL21738148 | 0.81 | HRH3 (0.43) | HRH3LMNACHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21846690 | 0.80 | HRH3 (0.47) | HRH3HTTCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL23583246 | 0.78 | HRH3 (0.41) | HRH3HSD11B1 | |
| SCHEMBL14471383 | 0.77 | HRH3 (0.60) | HRH3HTTLMNAALDH1A1TSHR | |
| SCHEMBL26790076 | 0.77 | HTT (0.46) | HRH3HTTLMNACHRNB2CHRNA3 | |
| SCHEMBL26139057 | 0.76 | ATM (0.38) | HRH3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL21738123 | 0.75 | HRH3 (0.41) | HRH3HTTLMNAALDH1A1 | |
| SCHEMBL13621132 | 0.74 | HTT (0.50) | HRH3HTTLMNACHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | HRH3 932/4885HTT 3929/4885LMNA 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.